Featured Editorial

  1. DDW 2026 Signalled The Next Era Of Competitive Landscape In IBD 6/2/2026

    At the DDW 2026 meeting, the IBD landscape was portrayed as increasingly competitive and diversified, with emerging players and novel mechanisms challenging established standards of care.

  2. From Exosomes To Nanodrugs: Advancing Therapeutic Delivery For CNS Repair 6/1/2026

    Exosomes are biological vesicles used for cellular communication that can overcome CNS barriers, delivering therapeutic cargo for CNS and optic nerve injuries.

  3. Risk Is the Spine: What The First 100 QMSR Inspections Reveal 5/29/2026

    The FDA has now completed just over 100 inspections under its new Quality Management System Regulation, and the agency has begun sharing preliminary observations from those inspections.

  4. Advancing Autologous Stem Cell Engineering For Diabetes And Vision Loss 5/28/2026

    Advances in autologous stem cell and biomaterial engineering are transforming the future of regenerative medicine by enabling scalable, patient-derived therapies.

  5. The Hidden Operational Complexities Of Home Infusion 5/20/2026

    Home infusion can lower costs and improve access, but requires complex coordination, patient readiness, logistics, and monitoring to ensure safe and effective care.

  6. Spine Care Redefined: Autologous Cell Therapy For Degenerative Disc Disease 5/19/2026

    Autologous intradiscal therapy integrates delivery and biology into one system, highlighting the potential of cell therapies in complex, localized disease environments.

  7. Surgical Therapeutic Design: Key Considerations In Formulation And Delivery 5/18/2026

    Conventional antibiotic prophylaxis often fails to maintain therapeutic levels at the surgical site over time; controlled-release local antibiotics can solve this.

  8. Need A Drug Delivery Conversation Starter? Try Target Product Profile 5/18/2026

    In this article, Chief Editor Tom von Gunden explores the need for and existence of cross-functional communication during drug product development and delivery device selection. He consults industry veterans with experience in various formulation or delivery roles at GSK and Merck. They identify the Target Product Profile (TPP) as the core concept guiding collaboration. 

  9. When Software Becomes Part Of The Medicine 5/15/2026

    Software is no longer just a support tool; it is central to real-world efficacy, transforming combination products by optimizing dosing, adherence, and technique.

  10. Prevascularized Bio-hybrid Organ Platforms Are Redefining Cell Therapy Delivery 5/14/2026

    Cell therapy success depends on a durable implantation environment, making delivery and sustainability central to efficacy and functional outcomes.